Indivior hands back PAM drug to Addex ahead of Supernus merger
Ahead of its upcoming merger with Supernus Pharmaceuticals, Indivior is returning its PAM drug program to partner Addex Therapeutics.
Indivior PLC
Indivior PLC (NASDAQ: INDV) is a specialty pharmaceutical company singularly focused on opioid use disorder (OUD), developing and commercializing evidence-based treatments such as the once-monthly injection Sublocade to support long-term recovery.
Company Info
Sector:Specialty Pharmaceuticals
Headquarters:Slough, England, UK
Founded:2014
Website:www.indivior.com/
Upcoming Milestones & Key Dates
Q4 2026
Corporate
Expected close of all-stock merger with Supernus Pharmaceuticals
Q3 2026
Financial
Third quarter 2026 financial results
Clinical Development Pipeline
Sublocade (buprenorphine extended-release)
Target: Mu-opioid receptor partial agonistPerseris (buprenorphine)
Target: Mu-opioid receptor partial agonistOpvee (nalmefene)
Target: Opioid receptor antagonistRecent News
Leadership Team
Joe Ciaffoni
Chief Executive Officer
Ryan Preblick
Chief Financial Officer
Dr. Ann Wheeler
Chief Medical Officer